Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT1002 SAD in healthy subjects
NCT04116840Phase 1Completed
- Sponsor
- Shaanxi Micot Technology Co., Ltd.
- Start
- Apr 2019
- Primary completion
- Aug 2019
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MT1002 in acute coronary syndrome (ACS), sponsored by Shaanxi Micot Technology Co., Ltd. Primary endpoints: Maximum observed concentration at 24 hours, Time to maximum concentration at 24 hours and 5 more. Started Apr 2019; status: completed.
02
Drugs
MT1002
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT04116840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04116840.